Partners

BioInvent’s partnering strategy is based on:

• Out-licensing opportunities with partners that can further develop and commercialize BioInvent’s proprietary pipeline assets.
• Research and development partnerships based on F.I.R.S.T™ and n-CoDeR®.
• Production of antibodies to external parties.

BioInvent has several licensing agreements and research collaborations with leading pharmaceutical companies:

	In December 2020, Pfizer selected antibodies directed at a previously-selected target under the cancer immunotherapy research collaboration. BioInvent is eligible for potential future development milestones in excess of USD 100 million if an antibody is developed through to commercialization, as well as up to double digit royalties.
	Co-developing (50/50 split of costs and profits) of oncolytic virus candidates for solid tumors, leveraging BioInvent’s n-CoDeR® and F.I.R.S.T™ platforms. Sharing of technology platforms, knowledge, and expertise.
	Clinical trial collaboration and supply agreement with Merck, to evaluate the combination of BI-1206 and KEYTRUDA® Exclusive licensing agreement with CASI Pharmaceuticals for BI-1206 in mainland China, Taiwan, Hong Kong and Macau
	Antibody discovery partnerships
	Research collaborations